Regulation of hyaluronan synthesis in vascular diseases and diabetes

Journal of Diabetes Research

Volumn 2015, Issue , 2015, Pages

  Moretto, Paola ^a   Karousou, Evgenia ^a   Viola, Manuela ^a   Caon, Ilaria ^a   D'Angelo, Maria Luisa ^a   De Luca, Giancarlo ^a   Passi, Alberto ^a   Vigetti, Davide ^a  

^a UNIVERSITY OF INSUBRIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

HYALURONIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; METFORMIN; N ACETYLGLUCOSAMINE; URIDINE TRIPHOSPHATE GLUCOSE 1 PHOSPHATE URIDYLYLTRANSFERASE; ADENYLATE KINASE;

ACYLATION; ARTICLE; ATHEROSCLEROSIS; DIABETES MELLITUS; ENZYME REGULATION; ENZYME SYNTHESIS; EXTRACELLULAR MATRIX; HUMAN; NONHUMAN; NUTRIENT AVAILABILITY; PRIORITY JOURNAL; SMOOTH MUSCLE FIBER; VASCULAR DISEASE; ANIMAL; BIOSYNTHESIS; CARDIOVASCULAR DISEASES; CELL ADHESION; CELL DIFFERENTIATION; CYTOLOGY; GENE EXPRESSION REGULATION; INFLAMMATION; METABOLISM; MICROCIRCULATION; SMOOTH MUSCLE CELL;

ACETYLGLUCOSAMINE; ACYLATION; ADENYLATE KINASE; ANIMALS; CARDIOVASCULAR DISEASES; CELL ADHESION; CELL DIFFERENTIATION; DIABETES MELLITUS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; HYALURONIC ACID; INFLAMMATION; MICROCIRCULATION; MYOCYTES, SMOOTH MUSCLE; VASCULAR DISEASES;

EID: 84925326144     PISSN: 23146745     EISSN: 23146753     Source Type: Journal    
DOI: 10.1155/2015/167283     Document Type: Article

References (115)

1. V.L. Roger, A. S. Go, D.M. Lloyd-Jones et al., "Heartdisease and stroke statistics-2012 update: a report from the American Heart Association," Circulation, vol. 125, no. 1, pp. e2-e220, 2012.
2. M. Brownlee, "Biochemistry and molecular cell biology of diabetic complications," Nature, vol. 414, no. 6865, pp. 813-820, 2001.
3. J. Nigro, N. Osman, A. M. Dart, and P. J. Little, "Insulin resistance and atherosclerosis," Endocrine Reviews, vol. 27, no. 3, pp. 242-259, 2006.
4. G. E. Davis and D. R. Senger, "Endothelial extracellularmatrix: biosynthesis, remodeling, and functions during vascular morphogenesis and neovessel stabilization," Circulation Research, vol. 97, no. 11, pp. 1093-1107, 2005.
5. R. Ross, "Atherosclerosis-an inflammatory disease," The New England Journal of Medicine, vol. 340, no. 2, pp. 115-126, 1999.
6. D. Vigetti, P. Moretto, M. Viola et al., "Matrixmetalloproteinase 2 and tissue inhibitors of metalloproteinases regulate human aortic smooth muscle cell migration during in vitro aging," The FASEB Journal, vol. 20, no. 8, pp. 1118-1130, 2006.
7. D. M. Gilkes, G. L. Semenza, and D. Wirtz, "Hypoxia and the extracellular matrix: drivers of tumour metastasis," Nature Reviews Cancer, vol. 14, no. 6, pp. 430-439, 2014.
8. T. C. Laurent and J. R. E. Fraser, "Hyaluronan," The FASEB Journal, vol. 6, no. 7, pp. 2397-2404, 1992.
9. D. Vigetti, M. Viola, E. Karousou et al., "Vascular pathology and the role of hyaluronan," The Scientific World Journal, vol. 8, pp. 1116-1118, 2008.
10. E. G. Karousou, M. Viola, A. Genasetti et al., "Application of polyacrylamide gel electrophoresis of fluorophore-labeled saccharides for analysis of hyaluronan and chondroitin sulfate in human and animal tissues and cell cultures," Biomedical Chromatography, vol. 19, no. 10, pp. 761-765, 2005.
11. T. N. Wight, "Arterial remodeling in vascular disease: a key role for hyaluronan and versican," Frontiers in Bioscience, vol. 13, no. 13, pp. 4933-4937, 2008.
12. D. Jiang, J. Liang, and P.W. Noble, "Hyaluronan in tissue injury and repair," Annual Review of Cell and Developmental Biology, vol. 23, pp. 435-461, 2007.
13. D. Jiang, J. Liang, and P.W. Noble, "Hyaluronan as an immune regulator in human diseases," Physiological Reviews, vol. 91, no. 1, pp. 221-264, 2011.
14. R. Stern and M. J. Jedrzejas, "Hyaluronidases: their genomics, structures, and mechanisms of action," Chemical Reviews, vol. 106, no. 3, pp. 818-839, 2006.
15. A. B. Csoka and R. Stern, "Hypotheses on the evolution of hyaluronan: a highly ironic acid," Glycobiology, vol. 23, no. 4, pp. 398-411, 2013.
16. R. Stern, A. A. Asari, and K. N. Sugahara, "Hyaluronan fragments: an information-rich system," European Journal of Cell Biology, vol. 85, no. 8, pp. 699-715, 2006.
17. D. Vigetti, E. Karousou, M. Viola, S. Deleonibus, G. deLuca, and A. Passi, "Hyaluronan: biosynthesis and signaling," Biochimica et Biophysica Acta-General Subjects, vol. 1840, no. 8, pp. 2452-2459, 2014.
18. A. J. Day and C. A. de la Motte, "Hyaluronan cross-linking: a protective mechanism in inflammation?" Trends in Immunology, vol. 26, no. 12, pp. 637-643, 2005.
19. F. Gao, J. R. Koenitzer, J. M. Tobolewski et al., "Extracellular superoxide dismutase inhibits inflammation by preventing oxidative fragmentation of hyaluronan," The Journal of Biological Chemistry, vol. 283, no. 10, pp. 6058-6066, 2008.
20. D. Vigetti and A. Passi, "Hyaluronan synthasesposttranslational regulation in cancer," Advances in Cancer Research, vol. 123, pp. 95-119, 2014.
21. P. H. Weigel and P. L. DeAngelis, "Hyaluronan synthases: a decade-plus of novel glycosyltransferases," Journal of Biological Chemistry, vol. 282, no. 51, pp. 36777-36781, 2007.
22. N. Itano, T. Sawai, M. Yoshida et al., "Three isoforms of mammalian hyaluronan synthases have distinct enzymatic properties," Journal of Biological Chemistry, vol. 274, no. 35, pp. 25085-25092, 1999.
23. K. Rilla, S. Oikari, T. A. Jokela et al., "Hyaluronan synthase 1 (HAS1) requires higher cellular udp-glcnac concentration than HAS2 and HAS3," The Journal of Biological Chemistry, vol. 288, no. 8, pp. 5973-5983, 2013.
24. X. Tian, J. Azpurua, C. Hine et al., "High-molecular-mass hyaluronan mediates the cancer resistance of the naked mole rat," Nature, vol. 499, no. 7458, pp. 346-349, 2013.
25. J. Y. L. Tien and A. P. Spicer, "Three vertebrate hyaluronan synthases are expressed during mouse development in distinct spatial and temporal patterns," Developmental Dynamics, vol. 233, no. 1, pp. 130-141, 2005.
26. M. Nardini, M. Ori, D. Vigetti, R. Gornati, I. Nardi, and R. Perris, "Regulated gene expression of hyaluronan synthases during Xenopus laevis development," Gene Expression Patterns, vol. 4, no. 3, pp. 303-308, 2004.
27. H. Siiskonen, R. Kärnä, J. M. Hyttinen, R. H. Tammi, M. I. Tammi, and K. Rilla, "Hyaluronan synthase 1 (HAS1) produces a cytokine-and glucose-inducible, CD44-dependent cell surface coat," Experimental Cell Research, vol. 320, no. 1, pp. 153-163, 2014.
28. D. Vigetti, M. Viola, E. Karousou, G. de Luca, and A. Passi, "Metabolic control of hyaluronan synthases," Matrix Biology, vol. 35, pp. 8-13, 2014.
29. M. G. Buse, "Hexosamines, insulin resistance, and the complications of diabetes: current status," The American Journal of Physiology: Endocrinology and Metabolism, vol. 290, no. 1, pp. E1-E8, 2006.
30. P. L. DeAngelis, "Monodisperse hyaluronan polymers: synthesis and potential applications," Current Pharmaceutical Biotechnology, vol. 9, no. 4, pp. 246-248, 2008.
31. W. Jing and P. L. DeAngelis, "Synchronized chemoenzymatic synthesis of monodisperse hyaluronan polymers," The Journal of Biological Chemistry, vol. 279, no. 40, pp. 42345-42349, 2004.
32. D. Vigetti, M. Ori, M. Viola et al., "Molecular cloning and characterization of UDP-glucose dehydrogenase from the amphibian Xenopus laevis and its involvement in hyaluronan synthesis," The Journal of Biological Chemistry, vol. 281, no. 12, pp. 8254-8263, 2006.
33. P. Libby, "Inflammation in atherosclerosis," Nature, vol. 420, no. 6917, pp. 868-874, 2002.
34. P. Libby, P. M. Ridker, and A. Maseri, "Inflammation and atherosclerosis," Circulation, vol. 105, no. 9, pp. 1135-1143, 2002.
35. M. Viola, E. Karousou, M. L. D'Angelo et al., "Regulated hyaluronan synthesis by vascular cells," International Journal of Cell Biology. In press.
36. R. D. Kenagy, S.-K. Min, A. W. Clowes, and J. D. Sandy, "Cell death-associated ADAMTS4 and versican degradation in vascular tissue," Journal of Histochemistry and Cytochemistry, vol. 57, no. 9, pp. 889-897, 2009.
37. R.D. Kenagy, A. H. Plaas, and T.N. Wight, "Versican degradation and vascular disease," Trends in Cardiovascular Medicine, vol. 16, no. 6, pp. 209-215, 2006.
38. F. D. Kolodgie, A. P. Burke, A. Farb et al., "Differential accumulation of proteoglycans and hyaluronan in culprit lesions: insights into plaque erosion," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 22, no. 10, pp. 1642-1648, 2002.
39. F. D. Kolodgie, A. P. Burke, T. N. Wight, and R. Virmani, "The accumulation of specific types of proteoglycans in eroded plaques: a role in coronary thrombosis in the absence of rupture," Current Opinion in Lipidology, vol. 15, no. 5, pp. 575-582, 2004.
40. J. Moncayo-Arlandi, Al. López-García, M. C. Fernández, A. C. Durán, and B. Fernández, "Osteoglycin deficiency does not affect atherosclerosis in mice," Atherosclerosis, vol. 237, no. 2, pp. 418-425, 2014.
41. A.-M. Heegaard, A. Corsi, C. C. Danielsen et al., "Biglycan deficiency causes spontaneous aortic dissection and rupture in mice," Circulation, vol. 115, no. 21, pp. 2731-2738, 2007.
42. A. A. H. Zen, G. Caligiuri, J. Sainz, M. Lemitre, C. Demerens, and A. Lafont, "Decorin overexpression reduces atherosclerosis development in apolipoprotein E-deficient mice," Atherosclerosis, vol. 187, no. 1, pp. 31-39, 2006.
43. R. Riessen, T. N. Wight, C. Pastore, C. Henley, and J. M. Isner, "Distribution of hyaluronan during extracellular matrix remodeling in human restenotic arteries and balloon-injured rat carotid arteries," Circulation, vol. 93, no. 6, pp. 1141-1147, 1996.
44. D. Vigetti, A. Genasetti, E. Karousou et al., "Proinflammatory cytokines induce hyaluronan synthesis andmonocyte adhesion in human endothelial cells through hyaluronan synthase 2 (HAS2) and the nuclear factor-kappaB (NF-kappaB) pathway," The Journal of Biological Chemistry, vol. 285, no. 32, pp. 24639-24645, 2010.
45. A. Genasetti, D. Vigetti, M. Viola et al., "Hyaluronan and human endothelial cell behavior," Connective Tissue Research, vol. 49, no. 3-4, pp. 120-123, 2008.
46. S. Chai, Q. Chai, C. C. Danielsen et al., "Overexpression of hyaluronan in the tunica media promotes the development of atherosclerosis," Circulation Research, vol. 96, no. 5, pp. 583-591, 2005.
47. Y. Kashima, M. Takahashi, Y. Shiba et al., "Crucial role of hyaluronan in neointimal formation after vascular injury," PLoS ONE, vol. 8, no. 3, Article ID e58760, 2013.
48. D. Vigetti, M. Rizzi, M. Viola et al., "The effects of 4-methylumbelliferone on hyaluronan synthesis, MMP2 activity, proliferation, and motility of human aortic smooth muscle cells," Glycobiology, vol. 19, no. 5, pp. 537-546, 2009.
49. D. Vigetti, M. Rizzi, P. Moretto et al., "Glycosaminoglycans and glucose prevent apoptosis in 4-methylumbelliferone-treated human aortic smooth muscle cells," Journal of Biological Chemistry, vol. 286, no. 40, pp. 34497-34503, 2011.
50. C. A. Cuff, D. Kothapalli, I. Azonobi et al., "The adhesion receptor CD44 promotes atherosclerosis by mediating inflammatory cell recruitment and vascular cell activation," The Journal of Clinical Investigation, vol. 108, no. 7, pp. 1031-1040, 2001.
51. L. G. Spagnoli, A. Orlandi, A. Mauriello et al., "Aging and atherosclerosis in the rabbit. 1. Distribution, prevalence and morphology of atherosclerotic lesions," Atherosclerosis, vol. 89, no. 1, pp. 11-24, 1991.
52. H.W. Stuhlsatz, H. Loffler, V. Mohanaradhakrishnan, S. Cosma, and H. Greiling, "Topographic and age-dependent distribution of the glycosaminoglycans in human aorta," Journal of Clinical Chemistry and Clinical Biochemistry, vol. 20, no. 10, pp. 713-721, 1982.
53. K. Murata and Y. Yokoyama, "Acidic glycosaminoglycans in human atherosclerotic cerebral arterial tissues," Atherosclerosis, vol. 78, no. 1, pp. 69-79, 1989.
54. A. M. F. Tovar, D. C. F. Cesar, G. C. Leta, and P. A. S. Mourao, "Age-related changes in populations of aortic glycosaminoglycans: species with low affinity for plasma low-density lipoproteins, and not species with high affinity, are preferentially affected," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 18, no. 4, pp. 604-614, 1998.
55. A. Chajara, B. Delpech, M.-N. Courel, J.-P. Basuyau, and H. Lévesque, "Effect of aging on neointima formation and hyaluronan, hyaluronidase and hyaluronectin production in injured rat aorta," Atherosclerosis, vol. 138, no. 1, pp. 53-64, 1998.
56. R. Varga, M. Eriksson, M. R. Erdos et al., "Progressive vascular smooth muscle cell defects in a mouse model of Hutchinson-Gilford progeria syndrome," Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 9, pp. 3250-3255, 2006.
57. D. Vigetti, M. Viola, E. Karousou et al., "Hyaluronan-CD44-ERK1/2 regulate human aortic smooth muscle cell motility during aging," The Journal of Biological Chemistry, vol. 283, no. 7, pp. 4448-4458, 2008.
58. T. Kita, N. Kume, M. Minami et al., "Role of oxidized LDL in atherosclerosis," Annals of the New York Academy of Sciences, vol. 947, pp. 199-206, 2001.
59. T. Kita, N. Kume, M. Yokode et al., "Oxidized-LDL and atherosclerosis. Role of LOX-1," Annals of the New York Academy of Sciences, vol. 902, pp. 95-102, 2000.
60. M. Viola, B. Bartolini, D. Vigetti et al., "Oxidized low density lipoprotein (LDL) affects hyaluronan synthesis in human aortic smooth muscle cells," Journal of Biological Chemistry, vol. 288, no. 41, pp. 29595-29603, 2013.
61. R. H. Tammi, A. G. Passi, K. Rilla et al., "Transcriptional and post-translational regulation of hyaluronan synthesis," FEBS Journal, vol. 278, no. 9, pp. 1419-1428, 2011.
62. D. Vigetti, A. Genasetti, E. Karousou et al., "Modulation of hyaluronan synthase activity in cellular membrane fractions," The Journal of Biological Chemistry, vol. 284, no. 44, pp. 30684-30694, 2009.
63. V. C. Hascall, A. Wang, M. Tammi et al., "The dynamic metabolism of hyaluronan regulates the cytosolic concentration of UDP-GlcNAc," Matrix Biology, vol. 35, pp. 14-17, 2014.
64. S. P. Evanko and T. N. Wight, "Intracellular localization of hyaluronan in proliferating cells," Journal of Histochemistry and Cytochemistry, vol. 47, no. 10, pp. 1331-1341, 1999.
65. A. C. Petrey and C. A. de la Motte, "Hyaluronan, a crucial regulator of inflammation," Frontiers in Immunology, vol. 5, article 101, 2014.
66. V. C. Hascall, A. K. Majors, C. A. de laMotte et al., "Intracellular hyaluronan: a new frontier for inflammation?" Biochimica et Biophysica Acta-General Subjects, vol. 1673, no. 1-2, pp. 3-12, 2004.
67. J. A. Hanover, M. W. Krause, and D. C. Love, "Bittersweet memories: linking metabolism to epigenetics through OGlcNAcylation," Nature Reviews Molecular Cell Biology, vol. 13, no. 5, pp. 312-321, 2012.
68. D. Vigetti, S. Deleonibus, P. Moretto et al., "Role of UDP-Nacetylglucosamine (GlcNAc) and O-GlcNacylation of hyaluronan synthase 2 in the control of chondroitin sulfate and hyaluronan synthesis," The Journal of Biological Chemistry, vol. 287, no. 42, pp. 35544-35555, 2012.
69. J. B. Thoden, T. M. Wohlers, J. L. Fridovich-Keil, and H. M. Holden, "Human UDP-galactose 4-epimerase. Accommodation of UDP-N-acetylglucosamine within the active site," The Journal of Biological Chemistry, vol. 276, no. 18, pp. 15131-15136, 2001.
70. G. W. Hart, M. P. Housley, and C. Slawson, "Cycling of Olinked beta-N-acetylglucosamine on nucleocytoplasmic proteins," Nature, vol. 446, no. 7139, pp. 1017-1022, 2007.
71. Q. Xu, C. Yang, Y. Du et al., "AMPK regulates histone H2B OGlcNAcylation," Nucleic Acids Research, vol. 42, no. 9, pp. 5594-5604, 2014.
72. L. K. Kreppel and G. W. Hart, "Regulation of a cytosolic and nuclear O-GlcNAc transferase. Role of the tetratricopeptide repeats," Journal of Biological Chemistry, vol. 274, no. 45, pp. 32015-32022, 1999.
73. D. Vigetti, S. Deleonibus, P. Moretto et al., "Natural antisense transcript for hyaluronan synthase 2 (HAS2-AS1) induces transcription of HAS2 via proteinO-GlcN acylation," The Journal of Biological Chemistry, vol. 289, no. 42, pp. 28816-28826, 2014.
74. D. R. Michael, A. O. Phillips, A. Krupa et al., "The human hyaluronan synthase 2 (HAS2) gene and its natural antisense RNA exhibit coordinated expression in the renal proximal tubular epithelial cell," The Journal of Biological Chemistry, vol. 286, no. 22, pp. 19523-19532, 2011.
75. M. Magistri, M. A. Faghihi, G. St Laurent, and C. Wahlestedt, "Regulation of chromatin structure by long noncoding RNAs: focus on natural antisense transcripts," Trends in Genetics, vol. 28, no. 8, pp. 389-396, 2012.
76. J. Y. Lee and A. P. Spicer, "Hyaluronan: a multifunctional, megaDalton, stealthmolecule," Current Opinion in Cell Biology, vol. 12, no. 5, pp. 581-586, 2000.
77. D. G. Hardie, "AMPK: a target for drugs and natural products with effects on both diabetes and cancer," Diabetes, vol. 62, no. 7, pp. 2164-2172, 2013.
78. D. G. Hardie, F. A. Ross, and S. A. Hawley, "AMPK: a nutrient and energy sensor that maintains energy homeostasis," Nature Reviews Molecular Cell Biology, vol. 13, no. 4, pp. 251-262, 2012.
79. D. Vigetti, M. Clerici, S. Deleonibus et al., "Hyaluronan synthesis is inhibited by adenosine monophosphate-activated protein kinase through the regulation of HAS2 activity in human aortic smooth muscle cells," Journal of Biological Chemistry, vol. 286, no. 10, pp. 7917-7924, 2011.
80. J. D. Stone, A. Narine, P. R. Shaver, J. C. Fox, J. R. Vuncannon, and D. A. Tulis, "AMP-activated protein kinase inhibits vascular smooth muscle cell proliferation and migration and vascular remodeling following injury," The American Journal of Physiology: Heart and Circulatory Physiology, vol. 304, no. 3, pp. H369-H381, 2013.
81. D. Nagata, R. Takeda, M. Sata et al., "AMP-activated protein kinase inhibits angiotensin II-stimulated vascular smoothmuscle cell proliferation," Circulation, vol. 110, no. 4, pp. 444-451, 2004.
82. L. Heickendorff, T. Ledet, and L.M. Rasmussen, "Glycosaminoglycans in the human aorta in diabetes mellitus: a study of tunica media from areas with and without atherosclerotic plaque," Diabetologia, vol. 37, no. 3, pp. 286-292, 1994.
83. M. Morita, S. Yano, Y. Ishibashi, N. Nakata, S. Kurioka, and T. Sugimoto, "Close relationship between serum hyaluronan levels and vascular function in patients with type 2 diabetes," Biomarkers, vol. 19, no. 6, pp. 493-497, 2014.
84. T. O. McDonald, R. G. Gerrity, C. Jen et al., "Diabetes and arterial extracellular matrix changes in a porcine model of atherosclerosis," Journal of Histochemistry and Cytochemistry, vol. 55, no. 11, pp. 1149-1157, 2007.
85. A. Sainio, T. Jokela, M. I. Tammi, and H. Järveläinen, "Hyperglycemic conditions modulate connective tissue reorganization by human vascular smooth muscle cells through stimulation of hyaluronan synthesis," Glycobiology, vol. 20, no. 9, pp. 1117-1126, 2010.
86. A. Wang and V. C. Hascall, "Hyaluronan structures synthesized by rat mesangial cells in response to hyperglycemia induce monocyte adhesion," The Journal of Biological Chemistry, vol. 279, no. 11, pp. 10279-10285, 2004.
87. A. Lewis, R. Steadman, P. Manley et al., "Diabetic nephropathy, inflammation, hyaluronan and interstitial fibrosis," Histology and Histopathology, vol. 23, no. 6, pp. 731-739, 2008.
88. A. Wang, C. de la Motte, M. Lauer, and V. Hascall, "Hyaluronan matrices in pathobiological processes," FEBS Journal, vol. 278, no. 9, pp. 1412-1418, 2011.
89. M. Bogdani, P. Y. Johnson, S. Potter-Perigo et al., "Hyaluronan and hyaluronan-binding proteins accumulate in both human type 1 diabetic islets and lymphoid tissues and associate with inflammatory cells in insulitis," Diabetes, vol. 63, no. 8, pp. 2727-2743, 2014.
90. M. Bogdani, E. Korpos, C. J. Simeonovic, C. R. Parish, L. Sorokin, and T. N. Wight, "Extracellular matrix components in the pathogenesis of type 1 diabetes," Current Diabetes Reports, vol. 14, no. 12, article 552, 2014.
91. C. P. Chen, W. Hung, and S. H. Lin, "Effectiveness of hyaluronic acid for treating diabetic foot: a systematic review and metaanalysis," Dermatologic Therapy, vol. 27, no. 6, pp. 331-336, 2014.
92. M. E. Edmonds, M. P. Blundell, M. E. Morris, E. M. Thomas, L. T. Cotton, and P. J. Watkins, "Improved survival of the diabetic foot: the role of a specialised foot clinic," The Quarterly Journal of Medicine, vol. 60, no. 232, pp. 763-771, 1986.
93. H. M. Rathur and A. J.M. Boulton, "Pathogenesis of foot ulcers and the need for offloading," Hormone and Metabolic Research, vol. 37, supplement 1, pp. S61-S68, 2005.
94. K. L. Andrews, M. T. Houdek, and L. J. Kiemele, "Wound management of chronic diabetic foot ulcers: from the basics to regenerative medicine," Prosthetics and Orthotics International, vol. 39, no. 1, pp. 29-39, 2015.
95. C. Katsumura, T. Sugiyama, K. Nakamuraa et al., "Effects of advanced glycation end products on hyaluronan photolysis: a new mechanism of diabetic vitreopathy," Ophthalmic Research, vol. 36, no. 6, pp. 327-331, 2004.
96. A. Neumann, R. Schinzel, D. Palm, P. Riederer, and G. Münch, "High molecular weight hyaluronic acid inhibits advanced glycation endproduct-inducedNF-kappaB activation and cytokine expression," FEBS Letters, vol. 453, no. 3, pp. 283-287, 1999.
97. H.-S. Wang, W.-H. Tung, K.-T. Tang et al., "TGF-β induced hyaluronan synthesis in orbital fibroblasts involves protein kinase C βII activation in vitro," Journal of Cellular Biochemistry, vol. 95, no. 2, pp. 256-267, 2005.
98. C. Slawson, R. J. Copeland, and G. W. Hart, "O-GlcNAc signaling: a metabolic link between diabetes and cancer?" Trends in Biochemical Sciences, vol. 35, no. 10, pp. 547-555, 2010.
99. R. J. Copeland, J.W. Bullen, and G.W. Hart, "Cross-talkbetween GlcNAcylation and phosphorylation: roles in insulin resistance and glucose toxicity," American Journal of Physiology-Endocrinology and Metabolism, vol. 295, no. 1, pp. E17-E28, 2008.
100. S. Özcan, S. S. Andrali, and J. E. L. Cantrell, "Modulation of transcription factor function by O-GlcNAc modification," Biochimica et Biophysica Acta, vol. 1799, no. 5-6, pp. 353-364, 2010.
101. P. H. Gæde, P. V. Jepsen, J. N. B. Larsen, G. V. Jensen, H.-H. Parving, and O. B. Pedersen, "The Steno type 2 study: intensive multifactorial treatment reduces the incidence of cardiovascular disease in patients with type 2 diabetes," Ugeskrift for Laeger, vol. 165, no. 26, pp. 2658-2661, 2003.
102. J. A. Marshall and D.H. Bessesen, "Dietary fat and the development of type 2 diabetes," Diabetes Care, vol. 25, no. 3, pp. 620-622, 2002.
103. L. Kang, L. Lantier, A. Kennedy et al., "Hyaluronan accumulates with high-fat feeding and contributes to insulin resistance," Diabetes, vol. 62, no. 6, pp. 1888-1896, 2013.
104. S. W. Choi and S. Friso, "Epigenetics: a new bridge between nutrition and health," Advances in Nutrition, vol. 1, no. 1, pp. 8-16, 2010.
105. M. A. Reddy and R. Natarajan, "Epigenetic mechanisms in diabetic vascular complications," Cardiovascular Research, vol. 90, no. 3, pp. 421-429, 2011.
106. D. M. Nathan, P. A. Cleary, J.-Y. C. Backlund et al., "Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes," The New England Journal of Medicine, vol. 353, no. 25, pp. 2643-2653, 2005.
107. M. A. Ihnat, J. E. Thorpe, and A. Ceriello, "Hypothesis: the 'metabolic memory', the new challenge of diabetes," Diabetic Medicine, vol. 24, no. 6, pp. 582-586, 2007.
108. A. Ceriello, M.A. Ihnat, and J. E. Thorpe, "The';Metabolicmemory': ismore than just tight glucose control necessary to prevent diabetic complications?" Journal of Clinical Endocrinology and Metabolism, vol. 94, no. 2, pp. 410-415, 2009.
109. D. Vigetti, M. Viola, E. Karousou et al., "Epigenetics in extracellular matrix remodeling and hyaluronan metabolism," FEBS Journal, vol. 281, no. 22, pp. 4980-4992, 2014.
110. B. Viollet, L. Lantier, J. Devin-Leclerc et al., "Targeting the AMPK pathway for the treatment of Type 2 diabetes," Frontiers in Bioscience (Landmark Ed), vol. 14, no. 9, pp. 3380-3400, 2009.
111. A. Patel, S. MacMahon, J. Chalmers et al., "Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes," The New England Journal of Medicine, vol. 358, no. 24, pp. 2560-2572, 2008.
112. R. Turner, "Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group," The Lancet, vol. 352, no. 9131, pp. 854-865, 1998.
113. J. A. Johnson, S. H. Simpson, E. L. Toth, and S. R. Majumdar, "Reduced cardiovascular morbidity and mortality associated with metformin use in subjects with type 2 diabetes," Diabetic Medicine, vol. 22, no. 4, pp. 497-502, 2005.
114. D. Micic, G. Cvijovic, V. Trajkovic, L. H. Duntas, and S. Polovina, "Metformin: its emerging role in oncology," Hormones, vol. 10, no. 1, pp. 5-15, 2011.
115. C. J. Bailey, "Metformin: effects on micro and macrovascular complications in type 2 diabetes," Cardiovascular Drugs and Therapy, vol. 22, no. 3, pp. 215-224, 2008.